Paydirt
KG
Insider

Kenneth Galbraith

Chair & CEO

Kenneth Galbraith (Chair & CEO) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in ZYME. The largest single filing was $1.4M of ZYME (54,343 sh across 2 lots, as filed), executed Jan 5.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.3M
shares × price, as filed
Last traded
Jan 12
Filed Jan 12
Open performance→
Volume by month
$2.1M$1.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Jan 2025 · sells $855KDec 2025 · sells $1.3MJan 2026 · sells $2.1M
Buys $0 Sells $4.2M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 3 filings

Sector per market data · by filing · past 12 months

Most traded names
ZYME ZYME ZYME · 0 buys · 4 sells 4 filings
Recent filings
ZYMESALE Zymeworks Inc. View filing → $690K
30,424 sh × $22.67
Exec Jan 12
Filed Jan 12 · 5:30 PM ET ZYMESALE Zymeworks Inc. View filing → $1.4M
54,343 sh across 2 lots
Exec Jan 5
Filed Jan 5 · 5:30 PM ET ZYMESALE Zymeworks Inc. View filing → $1.3M
47,528 sh × $27.02
Exec Dec 22 2025
Filed Dec 22 2025 · 5:30 PM ET ZYMESALE Zymeworks Inc. View filing → $855K
57,291 sh across 2 lots
Exec Jan 6 2025
Filed Jan 6 2025 · 5:30 PM ET